BBLG (Bone Biologics) OCF Yield %: -133.73 (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BBLG Bone Biologics Corp BBLG
30 GF Score
Price $1.07
View Full Analysis

What is Bone Biologics OCF Yield %?

Bone Biologics BBLG -0.93% 30 OCF Yield % is -133.73 as of Jul. 25, 2026. GuruFocus rates BBLG with a GF Score™ of 30/100. Among 1,410 Biotechnology companies, Bone Biologics ranks worse than 92.27% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Bone Biologics's Trailing 12-Month Cash Flow from Operations is $-2.57 Mil, and Market Cap is $1.92 Mil. Therefore, Bone Biologics's OCF Yield % for today is -133.73%.

The historical rank and industry rank for Bone Biologics's OCF Yield % or its related term are showing as below:

BBLG' s OCF Yield % Range Over the Past 10 Years
Min: -133.73   Med: 0   Max: -133.73
Current: -133.73


During the past 12 years, the highest OCF Yield % of Bone Biologics was -133.73%. The lowest was -133.73%. And the median was %.

BBLG's OCF Yield % is ranked worse than
92.27% of 1410 companies
in the Biotechnology industry
Industry Median: -8.63 vs BBLG: -133.73

Bone Biologics's OCF Margin % for the quarter that ended in Mar. 2026 was %.


Bone Biologics OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Bone Biologics OCF Yield % Related Terms


Bone Biologics OCF Yield % Historical Data

* Premium members only.

The historical data trend for Bone Biologics's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bone Biologics OCF Yield % Chart

Bone Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.46 -107.39 -395.91 -148.61 -103.39

Bone Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -141.59 -27.04 -47.20 -109.88 -162.88

BBLG vs VRAX, PKTX, OGEN: OCF Yield % Comparison

For the Biotechnology subindustry, Bone Biologics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bone Biologics OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bone Biologics's OCF Yield % distribution charts can be found below:

* The bar in red indicates where Bone Biologics's OCF Yield % falls into.


BBLG
30GF Score
Bone Biologics Corp BBLG
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bone Biologics OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Bone Biologics's OCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-2.691 / 2.60275
=-103.39%

Bone Biologics's annualized OCF Yield % for the quarter that ended in Mar. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-0.804 * 4 / 1.9745
=-162.88%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -133.73 mean?
Bone Biologics (BBLG) has a OCF Yield % of -133.73 as of Jul. 25, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Bone Biologics and its competitors. According to the industry distribution chart, Bone Biologics ranks #1301 out of 1410 companies in the Biotechnology industry, placing it in the top 92.3%.
Is Bone Biologics' OCF Yield % too high?
Bone Biologics' current OCF Yield % is -133.73. Based on the distribution chart, Bone Biologics ranks #1301 out of 1410 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Bone Biologics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Bone Biologics' OCF Yield % compare to VRAX and PKTX?
According to the Biotechnology industry distribution chart, Bone Biologics ranks #1301 out of 1410 companies for OCF Yield %. This places Bone Biologics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Bone Biologics and its competitors. Bone Biologics's current OCF Yield % is -133.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bone Biologics stock overvalued right now?
Bone Biologics (BBLG) has a current OCF Yield % of -133.73. The current OCF Yield % is -133.73. Bone Biologics' overall GF Score™ is 30/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Bone Biologics (BBLG), the current OCF Yield % is -133.73 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bone Biologics Business Description

Address 2 Burlington Woods Drive, Suite 100, Burlington, MA, USA, 01803
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.
30GF Score

Get the complete analysis for BBLG

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.07
Price